Search
The 'i4MDS' consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read moreTravel Grants
Travel grant application is now open Apply here
Travel grants are intended to support young investigators to participate in the 7th European CAR T-cell Meeting; therefore, applicants should be 40 years of age or younger.
Young EHA Committee
Current committee members
Nuno Borges, United Kingdom (Chair)
Alba Maiques Diaz, Spain (Vice-Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Anna Avagyan, Armenia
Côme Bommier, France
Lorenzo Brunetti, Italy
Ana Filipa Marques Saraiva, Portugal
Eleni Gavriilaki, Greece
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Pedro Moura, Sweden
Rhiannon Newman, Finland
Marlies Vanden Bempt, Belgium
Carlo…
Meet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Meet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Turkey tutorial focused on lymphoma
The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.
Read moreEHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias
Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.
Read moreProfessor Degos awarded at the 17th Congress of EHA in Amsterdam
Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- »